Literature DB >> 3809595

The acute in vitro and in vivo radiosensitivity of human lung tumour lines.

G M Duchesne, J H Peacock, G G Steel.   

Abstract

Eleven human lung tumour lines have been established in xenograft or tissue culture, and the responses to acute irradiation of the 10 lines which cloned in soft agar were assayed. In vitro radiosensitivity was evaluated using the multitarget and linear quadratic models of cell survival and the surviving fraction at 2 Gy. Significant differences in the response of the different cell types were found, the large-cell phenotype exhibiting radioresistance, and small-cell carcinomas and adenocarcinomas being radiosensitive. No differences in the capacity of the different tumour types to repair radiation damage were demonstrated. In vivo and spheroid response was modified by the effects of hypoxia and cell-contact phenomena. The results suggested that hyperfractionation would be useful in the clinical management of adenocarcinoma and small-cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3809595     DOI: 10.1016/s0167-8140(86)80066-4

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3.

Authors:  H B Kwa; A H Verhoeven; J Storm; N van Zandwijk; W J Mooi; J Hilkens
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

2.  Tumor response to radiotherapy is dependent on genotype-associated mechanisms in vitro and in vivo.

Authors:  Jerry R Williams; Yonggang Zhang; Haoming Zhou; Daila S Gridley; Cameron J Koch; John F Dicello; James M Slater; John B Little
Journal:  Radiat Oncol       Date:  2010-08-12       Impact factor: 3.481

3.  A panel of human lung carcinoma lines: establishment, properties and common characteristics.

Authors:  G M Duchesne; J J Eady; J H Peacock; M F Pera
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.